Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Q1 Earnings and Revenues Beat Estimates

Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Ligand (LGND) Stock?

Galapagos

Kodiak Sciences Inc

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.

Top Biotech Stocks for Q2 2020

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

Ligand (LGND) Up 16.3% Since Last Earnings Report: Can It Continue?

BioMarin Pharmaceutical

Blueprint Medicines

Vertex Pharmaceuticals

The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.

5 Biotech Stocks to Buy for a Strong Growth Prognosis

Ligand Pharmaceuticals: Despite Loss Of Prime Asset, The Company Can Make Gains This Year

Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.

Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up

Ligand Pharmaceuticals, Inc. (LGND) CEO John Higgins on Q4 2019 Results - Earnings Call Transcript

Alkermes

LGND vs. ALKS: Which Stock Is the Better Value Option?

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report?

Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings.

Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2019 Results - Earnings Call Transcript

Ligand (LGND) delivered earnings and revenue surprises of -24.62% and 7.12%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates

Picking winners is a crucial investment skill that should be continually improved over time.

Eight Diamonds' September 2019 Best Pick - Ligand Pharmaceuticals

Ligand develops and acquires technologies to help pharmaceutical companies develop medicines.

Ligand Pharmaceuticals Is A Lower Risk Biotech With A Cash Generative And Diversified Business Model

Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Ligand (LGND) Surges: Stock Moves 6.3% Higher

Ligand Pharmaceuticals Inc. LGND, +1.79% disclosed Thursday that a new program to repurchase up to $500 million worth of stock over the next three years was approved by the company's board.

Ligand Pharmaceuticals approves new $500 million stock buyback program

Ligand is developing antibodies-based therapeutics for the treatment of diseases affecting several organ systems.

Ligand Pharmaceuticals And The OmniAb Platform

Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?

MannKind

Moderna

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

Comfort Systems USA

W. R. Grace & Co.

Merit Medical Systems

Everest RE Group

Spirit Airlines

USA Truck

Insiders sell stocks for many reasons, but the only reason they buy is that they believe they will profit. Check out these insider buying picks.

7 Stocks the Insiders Are Buying on Sale

CEO of Ligand Pharmaceuticals Inc (30-Year Financial, Insider Trades) John L Higgins (insider trades) bought 1,850 shares of LGND on 07/31/2019 at an average price of $95.45 a share.

Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $176,582 of Shares

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) shares are down 10.5% on Tuesday following the company’s earnings report, but one of the company’s most vocal critics and short sellers is leaning into its bearish trade.

News for Ligand Pharmaceuticals Stock (LGND)